On June 29, 2026, the FDA will decide whether to expand the label of Arcutis Biotherapeutics Inc.’s (ARQT) ZORYVE cream 0.3% to include treatment of plaque psoriasis in children aged 2 to 5 years.ZORYVE cream 0.3% is already approved for the treatment of plaque psoriasis in adults and children down to age 6.If approved for the proposed new indication, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2. PDE4 is an intracellular enzyme that is an established target in dermatology.ARQT closed Tuesday’s (June 2, 2026) trading at $20.79, down 3.17%.